Chiglitazar

How it works

Interactions

Background

Evidence quality

Highlighted claims

• Chiglitazar is a novel PPAR pan-agonist approved by China's NMPA for glycaemic control in adults with T2DM, as monotherapy or in combination with metformin. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
• Unlike selective PPAR agonists, chiglitazar simultaneously activates all three PPAR subtypes with a moderate and balanced agonist profile. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
• Concomitant use of other PPAR agonists and fibrate drugs is contraindicated in the chiglitazar trial. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
• A phase 2 trial demonstrated that chiglitazar significantly improved steatohepatitis and reduced liver fat in MASLD patients, with greater effect at the higher dose. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
• The short duration of the phase 2 trial underscores the need for the longer, larger study now being designed. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol